Why prostate cancer trial monitoring is essential in 2026
Prostate cancer is the second most common cancer in men worldwide, with over 300,000 new cases in the US annually. The treatment landscape for advanced and metastatic prostate cancer is one of the most commercially competitive in oncology — with approved agents from Janssen/J&J, Pfizer, Astellas, AstraZeneca, Bayer, and others competing across disease stages.
The competitive dynamics in 2026 prostate cancer trials center on several high-value questions:
- PSMA-targeted radioligand therapy — lutetium PSMA-617 (Pluvicto) approved for mCRPC; multiple follow-on programs exploring earlier disease settings, new isotopes (actinium-225), and combination partners; the most active mechanistic competition in prostate cancer
- Next-generation AR inhibitors — after enzalutamide, apalutamide, and darolutamide: novel AR degraders (ARV-110, KW-5626), allosteric inhibitors, and AR splice variant (AR-V7) targeting programs entering Phase 2
- PARP inhibitor combinations — olaparib + abiraterone and rucaparib approvals in HRRm patients; expanding to unselected populations and earlier settings; competitive with niraparib, talazoparib programs
- Bipolar androgen therapy (BAT) — high-dose testosterone paradoxically sensitizing AR-inhibitor-resistant tumors; academic and pharma combination programs entering trials
- Bispecific antibodies and CAR-T — PSMA × CD3 bispecifics (JNJ-63898081, CC-1 from Janssen), PSMA CAR-T programs from multiple academic and commercial groups
- Immunotherapy combinations — checkpoint inhibitors have largely failed in unselected prostate cancer; MSI-H and CDK12-mutant subtypes now being targeted in biomarker-selected trials
Track the prostate cancer trial landscape automatically
New prostate cancer trials register on ClinicalTrials.gov daily. Get a clean digest every morning.
Start 14-Day Free TrialWhat we monitor for prostate cancer
Our daily ClinicalTrials.gov pipeline can be configured for targeted prostate cancer monitoring:
- Condition keywords: "prostate cancer", "prostate adenocarcinoma", "mCRPC", "castration-resistant prostate cancer", "mCSPC", "nmCRPC", "biochemical recurrence"
- Mechanism/target keywords: "PSMA", "lutetium", "actinium", "AR degrader", "PARP inhibitor prostate", "bipolar androgen", "CDK12", "BRCA prostate"
- Disease stage: Keywords to distinguish localized, biochemically recurrent, nmCRPC, mCSPC, and mCRPC settings
- Phase filter: Phase 1 for early competitive intelligence, Phase 2/3 for near-term competitive threats
- Sponsor filter: Industry (commercial landscape) vs. all including NCI cooperative groups (SWOG, Alliance, ECOG)
The PSMA radioligand therapy competitive race
The approval of lutetium PSMA-617 (Pluvicto) by Novartis in 2022 for mCRPC opened one of the most competitive trial races in oncology. The competitive landscape now includes:
- Lutetium-177 PSMA programs: Novartis expanding Pluvicto into earlier disease stages (PSMAfore, TheraP-2 successors); Lantheus partnering with academic groups on PSMA theranostics
- Actinium-225 PSMA: Higher energy alpha-emitter; more potent but harder to manufacture; programs from Clarity Pharmaceuticals, ITM, RadioMedix and others; Phase 1/2 trials expanding
- PSMA-targeted ADCs: Multiple programs using PSMA as delivery vehicle for cytotoxic payloads instead of radioisotopes
- Combination strategies: RLT + PARP inhibitors, RLT + AR inhibitors, RLT + checkpoint inhibitors — dozens of combination trials now registering
For any team with prostate cancer commercial or investment interests, PSMA trial monitoring is now mandatory competitive intelligence.
Who uses prostate cancer trial monitoring
- Oncology BD teams at pharma and biotech — tracking competitor PSMA, AR, and PARP programs across disease stages
- Prostate cancer-focused investors — monitoring pipeline milestones and competitive positioning
- CROs and nuclear medicine programs — identifying enrollment competition for radioligand therapy trials
- Prostate cancer patient advocacy (PCF, ZERO) — keeping patients informed about trial availability by disease stage
- Academic urologists and oncologists — monitoring commercial pipeline for collaboration and IIT opportunities
Monitor the prostate cancer pipeline daily
Set up your prostate cancer alert profile in 2 minutes. Cancel anytime.
Start Free Trial — No Credit Card for 14 DaysPricing
Basic — $49/month: 3 disease/keyword profiles, daily digest, ClinicalTrials.gov monitoring.
Professional — $149/month: Unlimited profiles, phase and sponsor filters, digest frequency options.
Team — $299/month: Everything in Professional for up to 5 users.
All plans include a 14-day free trial. Not charged until day 15.